DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Recruiting

Phase 2

Hormonal TherapyDCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Sponsor:

QuantumLeap Healthcare Collaborative

Code:

NCT06075953

Conditions

Ductal Carcinoma in Situ

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tamoxifen

Exemestane

Letrozole

Anastrazole

Testosterone + Anastrazole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-19. This information was provided to ClinicalTrials.gov by QuantumLeap Healthcare Collaborative on 2025-12-17.